Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Non-Current Assets (2009 - 2025)

Grifols' (GIFLF) quarterly Non-Current Assets came in at $17.0 billion in Q4 2025, up 1.71% on a YoY basis from $16.8 billion in Q4 2024, and up 1.71% quarter-over-quarter from $16.8 billion in Q4 2024.

Analysis

Grifols (GIFLF) Non-Current Assets (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Non-Current Assets for 17 consecutive years, with $17.0 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 1.71% year-over-year to $17.0 billion; the trailing twelve-month figure through Dec 2025 stood at $17.0 billion (up 1.71% YoY), and the FY2025 full-year result was $16.5 billion, down 1.28% from the prior year.
  • Non-Current Assets grew to $17.0 billion in Q4 2025 per GIFLF's latest filing, from $16.8 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $17.0 billion in Q4 2025 and bottomed at $15.7 billion in Q4 2021.
  • Historically, Non-Current Assets has averaged $16.5 billion across 5 years, with a median of $16.8 billion in 2024.
  • The sharpest annual moves came in 2021 and 2023: Non-Current Assets grew 8.73% in 2021, then slipped 5.24% in 2023.
  • Over 5 years, Non-Current Assets stood at $15.7 billion in 2021, then gained by 7.48% to $16.9 billion in 2022, then decreased by 5.24% to $16.0 billion in 2023, then grew by 4.77% to $16.8 billion in 2024, then increased by 1.71% to $17.0 billion in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $17.0 billion, $16.8 billion, and $16.0 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 1.96 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 938.60 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 564.41 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 17.04 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 17.04 Bn
Dec 31, 2024 16.75 Bn
Dec 31, 2023 15.99 Bn
Dec 31, 2022 16.87 Bn
Dec 31, 2021 15.70 Bn
Dec 31, 2020 14.44 Bn
Sep 30, 2020 14.02 Bn
Mar 31, 2020 13.50 Bn
Dec 31, 2019 11.27 Bn
Sep 30, 2019 11.55 Bn
Mar 31, 2019 11.25 Bn
Dec 31, 2018 10.27 Bn
Sep 30, 2018 10.18 Bn
Jun 30, 2018 10.13 Bn
Mar 31, 2018 12.80 Bn
Dec 31, 2017 9.39 Bn
Jun 30, 2017 9.09 Bn
Dec 31, 2016 7.57 Bn
Sep 30, 2016 7.38 Bn
Jun 30, 2016 7.48 Bn